智通财经网·2025-11-26 02:39Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has seen its stock price increase by over 4%, currently trading at 7.49 HKD, following the approval of its drug registration certificate for a new compound anesthetic cream by the National Medical Products Administration of China [1] Company Summary - The newly approved drug, Lidocaine and Prilocaine Cream, is intended for local skin anesthesia and is projected to generate sales of approximately 615 million CNY in public medical institutions in China by 2024 [1] - Xinhua Pharmaceutical is a significant global supplier of antipyretic and analgesic medications, with a product portfolio that includes Ibuprofen, Aspirin, and Meloxicam [1] Industry Summary - The current season is marked by a surge in respiratory infectious diseases, leading to increased demand for antiviral medications such as Oseltamivir and Marbofloxacin, with sales growth rates of 237% and 180% respectively over the past week [1]